Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584870 | 0.91 | HTT (0.47) | MEN1KMT2AHTTLMNAMAPT | |
| SCHEMBL3586895 | 0.89 | NPC1 (0.44) | LMNAMAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3591298 | 0.80 | P2RX3 (0.47) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL3584275 | 0.79 | NPC1 (0.42) | LMNAMAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3582065 | 0.79 | NPC1 (0.47) | KMT2ALMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3581021 | 0.79 | MAPT (0.44) | MEN1KMT2AHTTLMNAMAPT | |
| SCHEMBL3577519 | 0.79 | KDM4E (0.48) | KMT2ALMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3583505 | 0.79 | MAPT (0.46) | MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3586765 | 0.79 | MAPT (0.44) | HTTLMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3584786 | 0.79 | HTT (0.48) | MEN1KMT2AHTTLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104670-B3 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-09-21 | — | — | EP | claimed |
| EP-2104670-B1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-02-17 | — | — | EP | claimed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | claimed |
| CN-103588718-A | Novel triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA SA | 2014-02-19 | — | — | CN | claimed |
| CN-101679354-B | As GABABTriazinedione derivatives as receptor modulators | ADDEX PHARMA SA | 2013-12-18 | — | — | CN | claimed |
| EP-2662366-A1 | Novel triazinedione derivatives as GABA-B receptor modulators | ADDEX Pharma S.A. (CH) | 2013-11-13 | — | — | EP | claimed |
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | claimed |
| CN-101679354-A | As GABABNovel triazinedione derivatives as receptor modulators | ADDEX PHARMACEUTICALS SA | 2010-03-24 | — | — | CN | claimed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | claimed |
| EP-2104670-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | Addex Pharma SA (CH) | 2009-09-30 | — | — | EP | claimed |
| WO-2008056257-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMA S.A (CH) | 2008-05-15 | — | — | WO | claimed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8779129-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2014-07-15 | — | — | US | disclosed |
| CN-103588718-A | Novel triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA SA | 2014-02-19 | — | — | CN | disclosed |
| CN-101679354-B | As GABABTriazinedione derivatives as receptor modulators | ADDEX PHARMA SA | 2013-12-18 | — | — | CN | disclosed |
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| CN-101679354-A | As GABABNovel triazinedione derivatives as receptor modulators | ADDEX PHARMACEUTICALS SA | 2010-03-24 | — | — | CN | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-2104670-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | Addex Pharma SA (CH) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008056257-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMA S.A (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | MEN1 4868/4885KMT2A 4282/4885HTT 3215/4885 |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | MEN1 4868/4885KMT2A 4282/4885HTT 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.